LLY

1,142.47

+1.34%↑

JNJ

234.86

+2.94%↑

ABBV

229.14

+2.6%↑

UNH

400.05

+1.05%↑

MRK

121.94

+1.97%↑

LLY

1,142.47

+1.34%↑

JNJ

234.86

+2.94%↑

ABBV

229.14

+2.6%↑

UNH

400.05

+1.05%↑

MRK

121.94

+1.97%↑

LLY

1,142.47

+1.34%↑

JNJ

234.86

+2.94%↑

ABBV

229.14

+2.6%↑

UNH

400.05

+1.05%↑

MRK

121.94

+1.97%↑

LLY

1,142.47

+1.34%↑

JNJ

234.86

+2.94%↑

ABBV

229.14

+2.6%↑

UNH

400.05

+1.05%↑

MRK

121.94

+1.97%↑

LLY

1,142.47

+1.34%↑

JNJ

234.86

+2.94%↑

ABBV

229.14

+2.6%↑

UNH

400.05

+1.05%↑

MRK

121.94

+1.97%↑

Home・Lista de Ações・Denali Therapeutics Inc

Denali Therapeutics Inc

Abrir

SetorSaúde

19.24 -6.37

Comprar Vender

Visão Geral

Variação de preço das ações

24h

Atual

Mín

19.29

Máximo

20.53

Indicadores-chave
By Trading Economics
Rendimento	102K -128M
EPS	-0.69
Funcionários	507
EBITDA	-9.8M -135M

Recomendações
By TipRanks
Recomendações	Compra Forte
Previsão para 12 meses	+76.27% upside

Dividendos
By Dow Jones
Próximos Ganhos	7 de ago. de 2026

Estatísticas de Mercado
By TradingEconomics
Capitalização de Mercado	277M 3.2B
Abertura anterior	25.61
Fecho anterior	19.24

Sentimento de Notícias

By Acuity

67%

33%

292 / 344 Ranking em Healthcare

Denali Therapeutics Inc Gráfico

O desempenho passado não é um indicador confiável de resultados futuros.

Notícias Relacionadas

4 de jun. de 2026, 21:51 UTC

Grandes Movimentos do Mercado

Merlin Shares Rally After Defense Department's Design Review Wraps

4 de jun. de 2026, 23:46 UTC

Conversa de Mercado

U.S. Jobs Data May Offer Bullish Catalyst for Dollar Vs. Yen -- Market Talk

4 de jun. de 2026, 23:44 UTC

Conversa de Mercado

Nikkei May Decline Amid Middle East Uncertainty -- Market Talk

4 de jun. de 2026, 23:42 UTC

Aquisições, Fusões, Aquisições de Empresas

Energy Resources of Australia: Court to Decide on Rio Tinto Compulsory Acquisition Request

4 de jun. de 2026, 23:41 UTC

Aquisições, Fusões, Aquisições de Empresas

Energy Resources of Australia to Enter Trading Halt

4 de jun. de 2026, 23:34 UTC

Conversa de Mercado

Oil Edges Lower Amid Mixed Middle East Developments -- Market Talk

4 de jun. de 2026, 23:31 UTC

Conversa de Mercado

Global Forex and Fixed Income Roundup: Market Talk

4 de jun. de 2026, 23:31 UTC

Conversa de Mercado

Mercury NZ Loses Bull Despite Sector Earnings Powering Up -- Market Talk

4 de jun. de 2026, 23:31 UTC

Conversa de Mercado

Global Equities Roundup: Market Talk

4 de jun. de 2026, 23:08 UTC

Conversa de Mercado

Narrowing Rate Differentials Make Australian Dollar Less Attractive Versus USD -- Market Talk

4 de jun. de 2026, 22:41 UTC

Conversa de Mercado

Australia Shares Set to Rise at the Open -- Market Talk

4 de jun. de 2026, 20:50 UTC

Conversa de Mercado

Financial Services Roundup: Market Talk

4 de jun. de 2026, 20:44 UTC

Aquisições, Fusões, Aquisições de Empresas

RTX Stock Rises After Catching an Upgrade. Why This Analyst Is Bullish. -- Barrons.com

4 de jun. de 2026, 20:16 UTC

Conversa de Mercado

Mexican Demand Indicators Show Signs of Life -- Market Talk

4 de jun. de 2026, 20:15 UTC

Aquisições, Fusões, Aquisições de Empresas

Gilead Sciences And Lakefront Complete Acquisition Of Ouro Medicines To Further Expand Inflammation Pipeline >GILD

4 de jun. de 2026, 19:46 UTC

Conversa de Mercado

Treasury Yields Decline Ahead of U.S. Payrolls -- Market Talk

4 de jun. de 2026, 19:38 UTC

Conversa de Mercado

Oil Futures Retreat After 3-Session Winning Streak -- Market Talk

4 de jun. de 2026, 19:30 UTC

Conversa de Mercado

U.S. Natural Gas Futures Rise on Weather, Storage Data -- Market Talk

4 de jun. de 2026, 18:47 UTC

Aquisições, Fusões, Aquisições de Empresas

Google Stock Attracts Cathie Wood's ARK and Berkshire Hathaway. That's Rare. -- Barrons.com

4 de jun. de 2026, 18:38 UTC

Ganhos

Money Quote: Tech Weakness in Context -- WSJ

4 de jun. de 2026, 18:24 UTC

Ganhos

Quantinuum, Broadcom, UnitedHealth, and More Stocks That Explain Today's Market -- Barrons.com

4 de jun. de 2026, 17:09 UTC

Conversa de Mercado

Retest of $55k Seen Possible for Bitcoin -- Market Talk

4 de jun. de 2026, 16:58 UTC

Ganhos

Broadcom, UnitedHealth, Blackstone, Ciena, and More Stocks That Explain Today's Market -- Barrons.com

4 de jun. de 2026, 16:46 UTC

Conversa de Mercado

Strategy BTC Sale Continues to Weigh on Prices -- Market Talk

4 de jun. de 2026, 16:38 UTC

Ganhos

UnitedHealth Stock Rises. Why the Health Insurer Is Leading the Dow to Sharp Gains. -- Barrons.com

4 de jun. de 2026, 16:20 UTC

Conversa de Mercado

Financial Services Roundup: Market Talk

4 de jun. de 2026, 16:20 UTC

Conversa de Mercado

Auto & Transport Roundup: Market Talk

4 de jun. de 2026, 16:13 UTC

Conversa de Mercado

On Again, Off Again Deals Keep Oil Market on Edge -- Market Talk

4 de jun. de 2026, 16:11 UTC

Conversa de Mercado

Copper Market Is Awaiting Key U.S. Tariff Decision -- Market Talk

4 de jun. de 2026, 15:56 UTC

Conversa de Mercado

Copper Rises Amid Hormuz Disruptions, U.S. Stockpiling -- Market Talk

Comparação entre Pares

Variação de preço

Denali Therapeutics Inc Previsão

Preço-alvo

By TipRanks

76.27% parte superior

Previsão para 12 meses

Média 35.5 USD 76.27%

Máximo 42 USD

Mínimo 23 USD

Com base em 13 analistas de Wall Street que oferecem metas de preço de 12 meses para Denali Therapeutics Inc - Dist nos últimos 3 meses.

Consenso de Avaliação

By TipRanks

Compra Forte

13 ratings

Comprar

Manter

Vender

Com base em 13 analistas que deram avaliações de ações para Denali Therapeutics Inc - Dist nos últimos 3 meses.

Sentimento

By Acuity

292 / 344 Ranking em Saúde

Informação Financeira

Custos administrativos e de venda

Custos Operacionais

Lucro antes de imposto

Vendas

Custo das vendas

Lucro bruto sobre vendas

Despesa com juros da dívida

EBITDA

Resultado Operacional

Sobre Denali Therapeutics Inc

Denali Therapeutics Inc., a biopharmaceutical company, develops a portfolio of product candidates engineered to cross the blood-brain barrier for neurodegenerative diseases and lysosomal storage diseases in the United States. The company's transport vehicle (TV)-enabled programs include DNL310 ETV, an IDS enzyme replacement therapy program for MPS II; TAK-594/DNL593 which is in Phase 1/II for frontotemporal dementia-granulin; DNL126 program for MPS IIIA; and DNL622 for MPS I, as well as other preclinical programs that target amyloid beta and HER2. Its brain-penetrant small molecule programs comprise BIIB122/DNL151 LRRK2 inhibitor program for Parkinson's disease; SAR443820/DNL788 RIPK1 inhibitor program for CNS disease; DNL343 eIF2B Activator program for amyotrophic lateral sclerosis; and SAR443122/DNL758 RIPK1 inhibitor program for peripheral inflammatory diseases. It also provides early stage program include TAK-594/DNL593 program for FTD-GRN; DNL126 program for MPS IIIA, a Sanfilippo Syndrome A; DNL622 for MPS I which is Hurler syndrome; Antibody Transport Vehicle Amyloid beta program; Oligonucleotide Transport Vehicle platform, a novel class of biotherapeutics to address the root cause of diseases through modulation of gene expression; and other TV-enabled discovery programs. The company has collaboration agreements with Biogen MA Inc. and Biogen International GmbH; Genzyme Corporation; Takeda Pharmaceutical Company Limited; F-star Gamma Limited, F-star Biotechnologische Forschungs-und Entwicklungsges m.b.H, and F-star Biotechnology Limited; and Genentech, Inc. The company was formerly known as SPR Pharma Inc. and changed its name to Denali Therapeutics Inc. in March 2015. Denali Therapeutics Inc. was incorporated in 2013 and is headquartered in South San Francisco, California.